WO2023139475 - PROMOTER FOR THE EXPRESSION OF GENES IN PARTICULAR EGR2-POSITIVE CELLS IN LAYER 2/3 OF MOUSE CORTEX
National phase entry:
Publication Number
WO/2023/139475
Publication Date
27.07.2023
International Application No.
PCT/IB2023/050389
International Filing Date
17.01.2023
Title **
[English]
PROMOTER FOR THE EXPRESSION OF GENES IN PARTICULAR EGR2-POSITIVE CELLS IN LAYER 2/3 OF MOUSE CORTEX
[French]
PROMOTEUR DE L'EXPRESSION DE GÈNES DANS LES CELLULES PARTICULIÈREMENT POSITIVES À L'EGR2 DANS LA COUCHE 2/3 DU CORTEX DE LA SOURIS
Applicants **
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH
Inventors
KELLER, Georg
OYIBO, Hassana
Priority Data
22152306.1
19.01.2022
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1908 | |
| EPO | Filing, Examination, Granting | 8149 | |
| Japan | Filing, Examination, Granting | 2045 | |
| South Korea | Filing, Examination, Granting | 1803 | |
| USA | Filing, Examination, Granting | 7140 |
Total:
21,045
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1, or of a nucleic acid sequence of at least 700 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule leads to the specific expression in layer 2/3 of mouse cortex of an exogenous gene in a particular population of EGR2-positive cells when a nucleic acid sequence coding for said exogenous gene is operatively linked to said isolated nucleic acid molecule, said particular population of EGR2-positive cells being characterized in that it also expresses ACTA2, ADORA3 and MYH11.[French]
La présente invention concerne une molécule d'acide nucléique isolée comprenant, ou consistant en, la séquence d'acide nucléique de SEQ ID NO: 1, ou en une séquence d'acide nucléique d'au moins 700 pb possédant au moins 80 % d'identité avec ladite séquence de SEQ ID NO : 1, ladite molécule d'acide nucléique isolée conduisant à l'expression spécifique, dans la couche 2/3 du cortex de souris, d'un gène exogène dans une population particulière de cellules EGR2-positives lorsqu'une séquence d'acide nucléique codant pour ledit gène exogène est liée de manière fonctionnelle à ladite molécule d'acide nucléique isolée, ladite population particulière de cellules EGR2-positives étant caractérisée en ce qu'elle exprime également ACTA2, ADORA3 et MYH11.